Current Report Filing (8-k)
December 31 2014 - 8:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event
reported): December 30, 2014
ARNO THERAPEUTICS, INC.
(Exact name of registrant as specified in
its charter)
Delaware
(State or other jurisdiction of incorporation)
000-52153 |
|
52-2286452 |
(Commission File Number) |
|
(IRS Employer |
|
|
Identification No.) |
200 Route 31 North, Suite 104
Flemington, NJ 08822
(Address of principal executive offices
and Zip Code)
(862) 703-7170
(Registrant’s telephone number, including
area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ¨ | Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-14(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Arno Therapeutics, Inc. (the “Company”)
has outstanding 2012 Series B Common Stock Purchase Warrants (the “Series B Warrants”) to purchase an aggregate of
approximately 6.2 million shares of the Company’s common stock, as well as 2013 Series E Common Stock Purchase Warrants (the
“Series E Warrants”) to purchase an aggregate of approximately 12.8 million shares of the Company’s common stock.
Both the Series B Warrants and the Series E Warrants are exercisable at a per share price of $2.40 and were set to expire on December
31, 2014. On December 30, 2014, the Company notified the holders of the Series B Warrants and the Series E Warrants that the Company
has extended the expiration date of such warrants to January 31, 2015.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: December 31, 2014
|
Arno Therapeutics, Inc. |
|
|
|
|
|
|
By: |
/s/ Lawrence A. Kenyon |
|
|
|
Lawrence A. Kenyon |
|
|
|
Chief Operating Officer and Chief |
|
|
|
Financial Officer |
|
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From May 2024 to Jun 2024
Arno Therapeutics (CE) (USOTC:ARNI)
Historical Stock Chart
From Jun 2023 to Jun 2024